$SNY News

Sanofi-ADR (NASDAQ:SNY): A Dividend Quality Candidate with Solid Profitability

EU EMA Announces Sanofi Winthrop Industrie Withdrew Its Application For The Use Of Dupixent In The Treatment Of Adults With Moderate-To-Severe Bullous Pemphigoid On June 24

Why the Amlitelimab Setback Isn’t Enough to Sink Sanofi’s Multi-Billion Dollar Engine

Sanofi 2026 Q2 - Results - Earnings Call Presentation

Sanofi (NASDAQ:SNY) Screens as Undervalued Value Stock with Solid Profitability

Antipodes Exited Sanofi (SNY) After Repeated Pipeline Setbacks

Sanofi Says Weak Decision-Making Hurt Pipeline, Promises More Disciplined R&D

Sanofi Sees FY2026 Sales $55.789B vs $55.850B Est

Sanofi Q2 Adj. EPS $1.21 Beats $1.09 Estimate, Sales $13.482B Beat $12.650B Estimate

Sanofi (ENXTPA:SAN) Stops Amlitelimab In Eczema And Expands Aqemia AI Pact

Sanofi abandons eczema drug approval efforts in another blow to OX40 class

Press Release: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews

Press Release: Sanofi evolves its Executive Committee to support its next strategic chapter

Aqemia and Sanofi Expand Their Research Collaboration

Sanofi-ADR (NASDAQ:SNY) Offers a High Dividend Yield With Strong Underlying Quality

SANOFI-ADR (NASDAQ:SNY): A Decent Value Stock With Strong Fundamentals and an Undervalued Profile

Sanofi (ENXTPA:SAN) Could Be 21% Undervalued As FDA Clears Sarclisa Escena

Sanofi (ENXTPA:SAN) Wins FDA Nod For Sarclisa Escena As EU Opens Antitrust Probe

Sanofi Wins FDA Approval for Wearable Injector Form of Blood Cancer Drug

Sanofi's Subcutaneous Sarclisa Escena Receives FDA Approval To Treat Multiple Myeloma